Skip to main content
    A

    Anavex Life Sciences Corp (AVXL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.82
    -0.12 (-12.42%)

    Market Cap: $86.53M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Anavex Life Sciences Corp (AVXL) Financials: Revenue, Profit and Cash Flow

    Updated Jul 30, 2026. Financial statements from company filings, amounts in US dollars.

    Anavex Life Sciences reported revenue of $0 for the fiscal year ended Sep 30, 2025. That year, net income was -$46.38M, operating cash flow was -$39.04M and free cash flow was -$39.04M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of $7.82M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Sep 2025, with an operating loss of $51.41M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Sep 2025$0N/AN/AN/AN/A
    Sep 2024$0N/AN/AN/AN/A
    Sep 2023$0N/AN/AN/AN/A
    Sep 2022$0N/AN/AN/AN/A
    Sep 2021$0N/AN/AN/AN/A
    Sep 2020$0N/AN/AN/AN/A
    Sep 2019$0N/AN/AN/AN/A
    Sep 2018$0N/AN/AN/AN/A
    Sep 2017$0N/AN/AN/AN/A
    Sep 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Sep 2016 to Sep 2025

    Income Statement

    In the fiscal year ended Sep 2025, the net loss widened from the year before. In the quarter ended Jun 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Research and development$37.59M$41.84M$43.72M$37.92M$32.98M$25.23M$22.26M$13.34M$10.67M$7.25M
    Operating income-$51.41M-$52.88M-$55.76M-$50.99M-$42.00M-$31.09M-$29.11M-$19.33M-$15.68M-$15.59M
    Net income-$46.38M-$43.00M-$47.51M-$47.98M-$37.91M-$26.28M-$26.29M-$17.25M-$13.46M-$14.74M
    EBITDAN/A-$52.61MN/AN/AN/A-$30.81MN/AN/A-$15.65M-$15.42M
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating income$6.74M-$6.48M-$6.78M-$10.84M-$14.46M-$12.51M-$13.59M-$14.27M-$14.60M-$12.62M-$11.38M-$12.66M
    Net income$7.82M-$5.34M-$5.68M-$9.83M-$13.24M-$11.20M-$12.11M-$11.62M-$12.21M-$10.55M-$8.62M-$10.15M
    Last 12 quarters

    Balance Sheet

    As of Sep 2025, cash and equivalents of $102.58M were 98.8% of total assets of $103.81M, against total liabilities of $8.95M.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Total assets$103.81M$135.57M$154.39M$152.71M$161.62M$34.54M$25.33M$26.21M$27.84M$9.50M
    Current assets$103.01M$135.57M$151.68M$152.71M$152.48M$29.69M$22.69M$26.05M$27.79M$9.45M
    Cash and equivalents$102.58M$132.19M$151.02M$149.16M$152.11M$29.25M$22.19M$22.93M$27.44M$9.19M
    Total liabilities$8.95M$15.30M$12.53M$10.21M$10.80M$7.31M$5.04M$3.88M$3.58M$3.19M
    Shareholder equity$94.87M$120.26M$141.85M$142.49M$150.82M$27.24M$20.29M$22.32M$24.25M$6.31M
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$120.14M$128.77M$132.99M$103.81M$102.43M$117.14M$124.04M$135.57M$141.53M$144.52M$148.07M$154.39M
    Total liabilities$7.69M$7.06M$6.37M$8.95M$11.47M$17.38M$13.13M$15.30M$11.75M$9.56M$12.49M$12.53M
    Cash and equivalents$118.33M$127.42M$131.75M$102.58M$101.16M$115.77M$120.78M$132.19M$138.76M$139.39M$143.76M$151.02M
    Shareholder equity$112.45M$121.71M$126.62M$94.87M$90.96M$99.76M$110.92M$120.26M$129.78M$134.96M$135.57M$141.85M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Sep 2025.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Operating cash flow-$39.04M-$30.81M-$27.79M-$24.24M-$30.38M-$21.29M-$18.53M-$12.58M-$9.02M-$9.24M
    Capital expenditures$0$0$0$4$4$4$0$0$0$3.02K
    Free cash flow-$39.04M-$30.81M-$27.79M-$24.24M-$30.38M-$21.29M-$18.53M-$12.58M-$9.02M-$9.24M
    Share repurchasesN/AN/AN/A$707.00K$5.55M$403.76K$0N/AN/AN/A
    Financing cash flow$9.43M$11.97M$29.65M$21.29M$153.24M$28.35M$17.78M$8.07M$27.27M$3.13M
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating cash flow-$4.44M-$7.15M-$8.60M-$12.46M-$5.86M-$12.12M-$6.66M-$5.18M-$11.66M-$7.32M-$5.85M-$7.65M
    Free cash flowN/A-$7.15M-$8.60M-$12.46M-$5.86M-$12.12M-$6.66M-$5.18M-$11.66M-$7.32M-$5.85M-$7.65M
    Last 12 quarters

    Frequently Asked Questions About AVXL

    What is Anavex Life Sciences' annual revenue?

    Anavex Life Sciences reported revenue of $0 for the fiscal year ended Sep 30, 2025.

    Is Anavex Life Sciences profitable?

    No. Anavex Life Sciences reported net income of -$46.38M for the fiscal year ended Sep 30, 2025.

    How much free cash flow does AVXL generate?

    For the fiscal year ended Sep 30, 2025, operating cash flow of -$39.04M minus capital expenditures of $0 produced free cash flow of -$39.04M.

    How much debt does Anavex Life Sciences have?

    The balance sheet dated Sep 30, 2025 reported cash and equivalents of $102.58M.